Literature DB >> 33141553

Glycosylation of Serum Clusterin in Wild-Type Transthyretin-Associated (ATTRwt) Amyloidosis: A Study of Disease-Associated Compositional Features Using Mass Spectrometry Analyses.

Celia M Torres-Arancivia, Deborah Chang, William E Hackett, Joseph Zaia, Lawreen H Connors.   

Abstract

Wild-type transthyretin-associated (ATTRwt) amyloidosis is an age-related disease that causes heart failure in older adults. This disease frequently features cardiac amyloid fibril deposits that originate from dissociation of the tetrameric protein, transthyretin (TTR). Unlike hereditary TTR (ATTRm) amyloidosis, where amino acid replacements destabilize the native protein, in ATTRwt amyloidosis, amyloid-forming TTR lacks protein sequence alterations. The initiating cause of fibril formation in ATTRwt amyloidosis is unclear, and thus, it seems plausible that other factors are involved in TTR misfolding and unregulated accumulation of wild-type TTR fibrils. We believe that clusterin (CLU, UniProtKB P10909), a plasma circulating glycoprotein, plays a role in the pathobiology of ATTRwt amyloidosis. Previously, we have suggested a role for CLU in ATTRwt amyloidosis based on our studies showing that (1) CLU codeposits with non-native TTR in amyloid fibrils from ATTRwt cardiac tissue, (2) CLU interacts only with non-native (monomeric and aggregated) forms of TTR, and (3) CLU serum levels in patients with ATTRwt are significantly lower compared to healthy controls. In the present study, we provide comprehensive detail of compositional findings from mass spectrometry analyses of amino acid and glycan content of CLU purified from ATTRwt and control sera. The characterization of oligosaccharide content in serum CLU derived from patients with ATTRwt amyloidosis is novel data. Moreover, results comparing CLU oligosaccharide variations between patient and healthy controls are original and provide further evidence for the role of CLU in ATTRwt pathobiology, possibly linked to disease-specific structural features that limit the chaperoning capacity of CLU.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33141553      PMCID: PMC8082438          DOI: 10.1021/acs.biochem.0c00590

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  66 in total

1.  Thermal behavior of proteins: heat-resistant proteins and their heat-induced secondary structural changes.

Authors:  T D Kim; H J Ryu; H I Cho; C H Yang; J Kim
Journal:  Biochemistry       Date:  2000-12-05       Impact factor: 3.162

2.  Glycosylation of Human Plasma Clusterin Yields a Novel Candidate Biomarker of Alzheimer's Disease.

Authors:  Hui-Chung Liang; Claire Russell; Vikram Mitra; Raymond Chung; Abdul Hye; Chantal Bazenet; Simon Lovestone; Ian Pike; Malcolm Ward
Journal:  J Proteome Res       Date:  2015-11-04       Impact factor: 4.466

3.  Dimeric transthyretin variant assembles into spherical neurotoxins.

Authors:  Kimiaki Matsubara; Mineyuki Mizuguchi; Kouhei Igarashi; Yoshinori Shinohara; Makoto Takeuchi; Atsushi Matsuura; Takayuki Saitoh; Yoshihiro Mori; Hiroyuki Shinoda; Keiichi Kawano
Journal:  Biochemistry       Date:  2005-03-08       Impact factor: 3.162

4.  Fibril in senile systemic amyloidosis is derived from normal transthyretin.

Authors:  P Westermark; K Sletten; B Johansson; G G Cornwell
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

Review 5.  Review: TTR amyloidosis-structural features leading to protein aggregation and their implications on therapeutic strategies.

Authors:  A M Damas; M J Saraiva
Journal:  J Struct Biol       Date:  2000-06       Impact factor: 2.867

6.  Evidence that clusterin has discrete chaperone and ligand binding sites.

Authors:  Johnathon N Lakins; Stephen Poon; Simon B Easterbrook-Smith; John A Carver; Martin P R Tenniswood; Mark R Wilson
Journal:  Biochemistry       Date:  2002-01-08       Impact factor: 3.162

7.  Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis.

Authors:  Belinda Ng; Lawreen H Connors; Ravin Davidoff; Martha Skinner; Rodney H Falk
Journal:  Arch Intern Med       Date:  2005-06-27

8.  Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens.

Authors:  Julie A Vrana; Jeffrey D Gamez; Benjamin J Madden; Jason D Theis; H Robert Bergen; Ahmet Dogan
Journal:  Blood       Date:  2009-10-01       Impact factor: 22.113

9.  Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis.

Authors:  E Ihse; A Ybo; Ob Suhr; P Lindqvist; C Backman; P Westermark
Journal:  J Pathol       Date:  2008-10       Impact factor: 7.996

10.  Tabulation of human transthyretin (TTR) variants, 2003.

Authors:  Lawreen Heller Connors; Amareth Lim; Tatiana Prokaeva; Violet A Roskens; Catherine E Costello
Journal:  Amyloid       Date:  2003-09       Impact factor: 7.141

View more
  2 in total

1.  Glycoproteomic Sample Processing, LC-MS, and Data Analysis Using GlycReSoft.

Authors:  Meizhe Wang; Asif Shajahan; Lauren E Pepi; Parastoo Azadi; Joseph Zaia
Journal:  Curr Protoc       Date:  2021-03

Review 2.  The Influence of Clusterin Glycosylation Variability on Selected Pathophysiological Processes in the Human Body.

Authors:  Ewa Janiszewska; Agnieszka Kmieciak; Monika Kacperczyk; Aleksandra Witkowska; Ewa Maria Kratz
Journal:  Oxid Med Cell Longev       Date:  2022-08-28       Impact factor: 7.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.